Agena at AMP 2023 - Workshop Speakers

Quick and Cost-Effective Molecular Profiling of Difficult NSCLC Samples

Ravindra Kolhe, MD, PhD, FCAP, Professor and Chair of Pathology, Medical College of Georgia

Dr. Kolhe is a Professor and Leon Henri Charbonnier Endowed Chair in Pathology at Augusta University. He is the inaugural Associate Dean for translation research at the Medical College of Georgia. He also serves as the Associate Cancer Center Director for Genomics at the Georgia Cancer Center. Currently, he leads an NCI-designated translational pathology laboratory for MATCH testing focused on comprehensive genomic testing in oncology.

Email Your Question

Darren W. Davis, PhD, Senior Vice President, Precision For Medicine

Dr. Davis is a visionary leader with decades of distinguished biotechnology and clinical translational biomarker research experience. He founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dr. Davis is dedicated and committed to improving the lives of patients with debilitating diseases.

Email Your Question

Guideline-Driven PGx Testing: A New, Targeted Testing Approach Covering AMP Tier 1 and Tier 2 Pharmacogenomic Recommendations

Chad Bousman, PhD, Associate Professor, Department of Medical Genetics, University of Calgary

Dr. Bousman is an Associate Professor in the Department of Medical Genetics at the University of Calgary, where he leads the Psychiatric Pharmacogenomics Laboratory. His program of research spans pharmacogenomic discovery and clinical implementation, with particular attention given to improving prescribing for mental health conditions across life stages. Dr. Bousman has published over 200 peer-reviewed papers and his research is supported by Canadian, US, and Australian funding bodies. He is a member of the American College of of Neuropsychopharmacology, Clinical Pharmacogenetics Implementation Consortium (CPIC), Pharmacogene Variation (PharmVar) Consortium, Pharmacogenomics Global Research Network (PGRN), and the Standardized Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative. He is also the founder and CEO of Sequence2Script Inc, a software company that assists laboratories with translating pharmacogenomic information into clinical action.

Email Your Question

Victoria M. Pratt, PhD, FACMG, Director of Scientific Affairs for Pharmacogenetics, Agena Bioscience

Dr. Pratt is the Past President of Association for Molecular Pathology. Dr. Pratt continues to serve on the Centers for Disease Control and Prevention (CDC) GeT-RM program for reference materials for Molecular Genetics, the National Academy of Medicine’s Roundtable on Genomics and Precision Health, and the American Medical Association’s (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory committee.

Dr. Pratt graduated with a Ph.D. in Medical and Molecular Genetics from Indiana University School of Medicine. Her fellowship training was in Ph.D. Medical and Clinical Molecular Genetics at Henry Ford Hospital, Detroit MI.

Email Your Question

Meet Our AMP 2024 Workshop Presenters

About Agena Bioscience

Connect